Diabetic Ketoacidosis Treatments

Find Diabetic Ketoacidosis Treatments

Generic Name

Empagliflozin

Brand Names
Glyxambi, Jardiance
FDA approval date: August 01, 2014
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
Form: Tablet

What is Glyxambi (Empagliflozin)?

GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (1.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

EASi-HF Reduced - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) < 40%

Summary: This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find out whether a medicine called vicadrostat, in combination with another medicine called empagliflozin, h...

EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease

Summary: This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this ...

EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) ≥40%

Summary: This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Participants are put into 2 groups by chance. Every partic...

Brand Information

    Glyxambi (empagliflozin and linagliptin)
    1INDICATIONS AND USAGE
    GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
    Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease
    2DOSAGE FORMS AND STRENGTHS
    GLYXAMBI tablets available as:
    • 10 mg empagliflozin/5 mg linagliptin are pale yellow, arc triangular, flat-faced, bevel-edged, film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "10/5".
    • 25 mg empagliflozin/5 mg linagliptin are pale pink, arc triangular, flat-faced, bevel-edged, film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "25/5".
    3CONTRAINDICATIONS
    GLYXAMBI is contraindicated in patients:
    • with a hypersensitivity to empagliflozin, linagliptin, or any of the excipients in GLYXAMBI, reactions such as anaphylaxis, angioedema, exfoliative skin conditions, urticaria, or bronchial hyperreactivity have occurred
    4ADVERSE REACTIONS
    The following important adverse reactions are described below and elsewhere in the labeling:
    • Diabetic Ketoacidosis in Patients with Type 1 Diabetes Mellitus and Other Ketoacidosis
    • Pancreatitis
    • Volume Depletion
    • Genitourinary Infections, including Urosepsis, Pyelonephritis, Necrotizing Fasciitis of the Perineum (Fournier's Gangrene), and Genital Mycotic Infections
    • Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues
    • Lower Limb Amputation
    • Hypersensitivity Reactions
    • Severe and Disabling Arthralgia
    • Bullous Pemphigoid
    • Heart Failure
    4.1Clinical Trials Experience
    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
    4.2Postmarketing Experience
    Additional adverse reactions have been identified during postapproval use of linagliptin and empagliflozin. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
    Gastrointestinal Disorders: Acute pancreatitis, including fatal pancreatitis [see , constipation, mouth ulceration, stomatitis
    Immune System Disorders: Hypersensitivity reactions including anaphylaxis, angioedema, and exfoliative skin conditions
    Infections: Necrotizing fasciitis of the perineum (Fournier's gangrene), urosepsis and pyelonephritis
    Metabolism and Nutrition Disorders: Ketoacidosis
    Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis, severe and disabling arthralgia
    Renal and Urinary Disorders: Acute kidney injury
    Skin and Subcutaneous Tissue Disorders: Bullous pemphigoid, skin reactions (e.g., rash, urticaria)
    5DRUG INTERACTIONS
    Table 3 describes clinically relevant interactions with GLYXAMBI.
    6OVERDOSAGE
    In the event of an overdose with GLYXAMBI, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Removal of empagliflozin by hemodialysis has not been studied, and removal of linagliptin by hemodialysis or peritoneal dialysis is unlikely.
    7DESCRIPTION
    GLYXAMBI tablets for oral use contain: empagliflozin and linagliptin.
    8HOW SUPPLIED/STORAGE AND HANDLING
    GLYXAMBI tablets are available as follows:
    10 mg/5 mg tablets: pale yellow, arc triangular, flat-faced, bevel-edged, film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "10/5".
    Bottles of 30 (NDC 0597-0182-30)
    25 mg/5 mg tablets: pale pink, arc triangular, flat-faced, bevel-edged, film-coated tablets. One side is debossed with the Boehringer Ingelheim company symbol; the other side is debossed with "25/5".
    Bottles of 30 (NDC 0597-0164-30)
    If repackaging is required, dispense in a tight container as defined in USP.
    9PATIENT COUNSELING INFORMATION
    Advise the patient to read the FDA-approved patient labeling (Medication Guide).
    10PRINCIPAL DISPLAY PANEL - 10 mg/5 mg Tablet Bottle Label
    NDC 0597-0182-90
    Glyxambi
    (empagliflozin and
    10 mg/5 mg
    DISPENSE WITH ACCOMPANYING MEDICATION GUIDE
    90 tablets
    Boehringer
    PRINCIPAL DISPLAY PANEL - 10 mg/5 mg Tablet Bottle Label
    11PRINCIPAL DISPLAY PANEL - 25 mg/5 mg Tablet Bottle Label
    NDC 0597-0164-90
    Glyxambi
    (empagliflozin and
    25 mg/5 mg
    DISPENSE WITH ACCOMPANYING MEDICATION GUIDE
    90 tablets
    Boehringer
    PRINCIPAL DISPLAY PANEL - 25 mg/5 mg Tablet Bottle Label
    Glyxambi has been selected.